Fred R. Hirsch, University of Colorado Denver (IMAGE)

University of Colorado Anschutz

Fred R. Hirsch, University of Colorado Denver

Caption

Fred R. Hirsch, MD, PhD, investigator at the University of Colorado Cancer Center and colleagues from 126 participating institutions show survival benefit of necitumumab as a first-line drug in squamous non-small cell lung cancer.

Credit

CU Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.